Skip to main content

Table 1 Baseline characteristics of the modified intent-to-treat population

From: Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial

 

(N = 14)

Patient characteristics

 Age, mean ± SD, years

49.3 ± 8.66

 Male sex, n (%)

14 (100)

 Race, n (%)

  White

12 (85.7)

  Asian

2 (14.3)

 Body mass index (BMI), mean ± SD, kg/m2

33.9 ± 6.96

 Smoking status, n (%)

  Never

4 (28.6)

  Current

5 (35.7)

  Former

5 (35.7)

 Comorbidities, n (%)

  Vascular disorders

7 (50.0)

   Hypertension

5 (35.7)

   Deep vein thrombosis

1 (7.1)

   Peripheral venous disease

1 (7.1)

   Thrombosis

1 (7.1)

   Varicose vein

1 (7.1)

  Respiratory, thoracic, and mediastinal disordersa

6 (42.9)

  Gastrointestinal disordersb

5 (35.7)

  Nervous system disordersc

4 (28.6)

  Psychiatric disordersd

4 (28.6)

  Elevated alanine aminotransferase

3 (21.4)

  Obesity

3 (21.4)

  General disorders and administration site conditionse

3 (21.4)

  Hepatobiliary disordersf

2 (14.3)

  Nephrolithiasis

2 (14.3)

  Erectile dysfunction

1 (7.1)

  Atrial fibrillation

1 (7.1)

Gout characteristics and assessments

 Prior occurrence of tophi, n (%)

13 (92.9)

 Time since first gout diagnosis, mean ± SD, years

13.8 ± 7.44

 Serum uric acid, mean ± SD, mg/dL

9.2 ± 2.49

 Prior oral urate-lowering therapy use

12 (85.7)

  Allopurinol

11 (78.6)

  Febuxostat

3 (21.4)

  Probenecid

0

  1. Baseline defined as the last assessment prior to the first pegloticase infusion
  2. aIncludes asthma, nasal congestion, deviated nasal septum, pulmonary mass, sleep apnea, and wheezing (n = 1 each)
  3. bIncludes alcoholic pancreatitis, dental caries, diarrhea, intestinal diverticulum, dyspepsia, gastrointestinal hemorrhage, and impacted tooth (n = 1 each)
  4. cIncludes headache (n = 2), cerebrovascular accident (n = 1), and paresthesia (n = 1)
  5. dIncludes anxiety, attention deficit/hyperactivity disorder, bipolar disorder, depression, abnormal orgasm, and insomnia (n = 1 each)
  6. eIncludes edema, peripheral edema, and ulcer (n = 1 each)
  7. fIncludes hepatic steatosis and NAFL (n = 1 each)